Indevus reiterated at strong buy by JMP

JMP Securities analyst Adam Cutler reiterated Indevus Pharmaceuticals, Inc. at strong buy on news of the company's strong third-quarter financial results. Revenues of $11.9 million came in slightly under JMP's estimate of $12.6 million but beat the Street consensus estimate of $11.0 million. The main near-term value-drivers continue to be Sanctura XR, pagoclone, and Nebido. Shares of the Lexington, Mass.-based biopharmaceutical company were up 13 cents, or 2.43%, at $5.47, on volume of 790,673 shares versus the three-month running average of 598,048 shares. (Nasdaq: IDEV)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.